antineoplastic agents

临床试验

Pharmacovigilance Assessment of Reporting of Cardiovascular Adverse Events With Antineoplastic Agents (PARCA)

计划入组 800,000 人 · 首次发布于 2024 年 5 月 10 日

Unknown

NCT03923036

Anticancer Vigilance Of Cardiac Events (AVOCETTE) in Metastatic Colorectal Cancer

计划入组 2,000 人 · 首次发布于 2019 年 4 月 22 日

已完成

NCT02484833

Erbitux MEtastatic Colorectal Cancer Strategy Study

计划入组 607 人 · 首次发布于 2015 年 6 月 30 日

药物

查看全部 303 →

Biotech

Approved

Pertuzumab(Perjeta, Perjeta-Herceptin, Phesgo)

生产企业：Hoffmann-La Roche Limited

相关疾病：Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC)，另有 3 项

Small Molecule

Approved

Panobinostat(Farydak)

相关疾病：Refractory Multiple Myeloma

C₂₁H₂₃N₃O₂

Biotech

Approved

Elotuzumab(Empliciti)

相关疾病：Refractory Multiple Myeloma

机构

查看全部 84 →

Ethos Technologies

United States

BeyondSpring

United States

Novo Nordisk AS

Sweden

资讯

查看全部 3083 →

去年

Experts Call for Paradigm Shift in Cancer Drug Dosing: Moving Beyond Maximum Tolerated Dose

去年

CDSCO Approves Phase I Trial for Jeevan Scientific's Bevacizumab Biosimilar in India

11个月前

临床试验

Pharmacovigilance Assessment of Reporting of Cardiovascular Adverse Events With Antineoplastic Agents (PARCA)

Anticancer Vigilance Of Cardiac Events (AVOCETTE) in Metastatic Colorectal Cancer

Erbitux MEtastatic Colorectal Cancer Strategy Study

药物

Pertuzumab(Perjeta, Perjeta-Herceptin, Phesgo)

Panobinostat(Farydak)

Elotuzumab(Empliciti)

机构

Ethos Technologies

BeyondSpring

Novo Nordisk AS

资讯

Experts Call for Paradigm Shift in Cancer Drug Dosing: Moving Beyond Maximum Tolerated Dose

CDSCO Approves Phase I Trial for Jeevan Scientific's Bevacizumab Biosimilar in India

Kashiv BioSciences and JAMP Pharma Launch Neutropenia Biosimilars in Canada